近年来糖尿病肾病引起慢性心衰的发病速度快速增长,目前还缺乏有效药物。finerenone是新一代口服非甾体类盐皮质激素受体拮抗剂,阻断醛甾酮导致的盐皮质激素受体过度激活产生的有害影响,可用于严重肾功能损害的患者。多项临床试验研究表明finerenone具有良好的安全性和有效性。主要从finerenone的药物概况、相关背景、合成路线、作用机制、药理作用和临床研究等方面进行介绍。

Recently, the disease developing speed of chronic heart failure induced by diabetic nephropathy is increasing rapidly, but now there is lack of effective drugs. finerenone is a new generation of oral non steroidal mineralcorticoid recept antagonist, and can block the harmful effects of the excessive activation of aldehydes and ketones, and can be used for patients with severe renal damage. Many clinical studies show that finerenone has a good safety and effectiveness. The drug situation, background, route of synthesis, mechanism and pharmacological action, and clinical trials researches of finerenone are reviewed in this paper.